2020
DOI: 10.17116/onkolog2020906151
|View full text |Cite
|
Sign up to set email alerts
|

Use of the measured diffusion coefficient for predicting overall and progression-free survival rates in patients with recurrent glioblastoma treated with bevacizumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 33 publications
0
0
0
Order By: Relevance